UPDATE: Cantor Fitzgerald Initiates Coverage on Bruker
According to a research report published Thursday, Cantor Fitzgerald has initiated Bruker (NASDAQ: BRKR) with a Buy rating and $16 PT.
In the report, Cantor Fitzgerald said, "Bruker has a highly diversified high-end scientific instrumentation portfolio targeting life science, applied, and industrial markets. In our view, the company is well positioned to capitalize on high-growth market segments over the next several years and deliver above-market top line growth, leveraging internal R&D and strategic tuckins. Additionally, with below sector average margins, Bruker has significant upside for margin expansion in the medium-term."
Bruker closed Wednesday at $13.39.
Latest Ratings for BRKR
|Dec 2014||Goldman Sachs||Downgrades||Buy||Sell|
|Nov 2014||Cantor Fitzgerald||Downgrades||Buy||Hold|
|Nov 2014||Bank of America||Maintains||Buy|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.